LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Slēgts

15.94 -2.51

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.81

Max

16.06

Galvenie mērījumi
By Trading Economics
Ienākumi	-23M -14M
Pārdošana	-22M 72M
EPS	-0.09
Peļņas marža	-18.944
Darbinieki	619
EBITDA	-23M -6.4M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+26.73% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-441M 2.4B
Iepriekšējā atvēršanas cena	18.45
Iepriekšējā slēgšanas cena	15.94

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

8.81 / 10.18 Atbalsts un pretestība

Adaptive Biotechnologies Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. febr. 23:53 UTC

Karstas akcijas

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

2026. g. 27. febr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

2026. g. 27. febr. 17:55 UTC

Karstas akcijas

Toronto Stocks Decline, But Remain On Track for Weekly Gains

2026. g. 27. febr. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

2026. g. 27. febr. 23:33 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

2026. g. 27. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 27. febr. 21:30 UTC

Peļņas

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

2026. g. 27. febr. 21:30 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

2026. g. 27. febr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

2026. g. 27. febr. 21:17 UTC

Peļņas

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026. g. 27. febr. 21:10 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

2026. g. 27. febr. 21:09 UTC

Iegādes, apvienošanās, pārņemšana

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

2026. g. 27. febr. 21:00 UTC

Peļņas

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

2026. g. 27. febr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

2026. g. 27. febr. 20:24 UTC

Tirgus saruna

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

2026. g. 27. febr. 20:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

2026. g. 27. febr. 20:12 UTC

Tirgus saruna

Nike Seen With Further Challenges in China -- Market Talk

2026. g. 27. febr. 19:44 UTC

Tirgus saruna

Gold Caps Historic Month -- Market Talk

2026. g. 27. febr. 19:39 UTC

Peļņas

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026. g. 27. febr. 19:38 UTC

Peļņas

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

2026. g. 27. febr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

2026. g. 27. febr. 18:45 UTC

Peļņas

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

2026. g. 27. febr. 18:45 UTC

Tirgus saruna

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

2026. g. 27. febr. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 27. febr. 17:07 UTC

Peļņas

Pemex Cuts 4Q Loss As Operating Results Improve

2026. g. 27. febr. 17:00 UTC

Tirgus saruna

Corn Rides Oil Momentum Higher -- Market Talk

2026. g. 27. febr. 16:31 UTC

Tirgus saruna

Canadian Economy Shows Resilience -- Market Talk

2026. g. 27. febr. 16:17 UTC

Tirgus saruna

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

2026. g. 27. febr. 15:49 UTC

Peļņas

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Adaptive Biotechnologies Corp Prognoze

Cenas mērķis

By TipRanks

26.73% augšup

Prognoze 12 mēnešiem

Vidējais 20.86 USD 26.73%

Augstākais 22 USD

Zemākais 20 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.81 / 10.18Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.